Compare
Align Technology Inc vs Steris PLC vs Edwards Lifesciences Corp vs Enovis Corp
| Latest fiscal year | Align Technology Inc ALGN | Steris PLC STE | Edwards Lifesciences Corp EW | Enovis Corp ENOV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.03B | $5.94B | $6.07B | $2.25B |
| Revenue growth (YoY) | +0.9% | +8.7% | +11.5% | +6.7% |
| Gross margin | 67.2% | 44.2% | 78.0% | 59.8% |
| Operating margin | 13.5% | 18.6% | 20.8% | -50.0% |
| Net margin | 10.2% | 13.2% | 17.6% | -52.7% |
| Net income | $410.35M | $782.30M | $1.07B | -$1.18B |
| EPS (Diluted) | $5.65 | $7.93 | $1.83 | -$20.75 |
| Operating cash flow | $593.22M | $1.34B | $1.60B | $217.29M |
| Free cash flow | $490.78M | $972.40M | $1.33B | $19.92M |
| Cash & equivalents | $1.09B | n/a | $2.94B | $36.39M |
| Total assets | $6.23B | $10.74B | $13.70B | $3.83B |
| Total liabilities | $2.18B | $3.54B | $3.36B | $2.34B |
| Shareholders' equity | $4.05B | $7.20B | $10.34B | $1.49B |
| Return on year-end equity | 10.1% | 10.9% | 10.3% | -79.5% |
| Shares outstanding | 71.36M | 97.80M | 580.70M | 57.19M |
Revenue, most recent five fiscal years
| Fiscal year | Align Technology Inc | Steris PLC | Edwards Lifesciences Corp | Enovis Corp |
|---|---|---|---|---|
| Latest | $4.03B Ended 2025-12-31 | $5.94B Ended 2026-03-31 | $6.07B Ended 2025-12-31 | $2.25B Ended 2025-12-31 |
| 1 year earlier | $4.00B Ended 2024-12-31 | $5.46B Ended 2025-03-31 | $5.44B Ended 2024-12-31 | $2.11B Ended 2024-12-31 |
| 2 years earlier | $3.86B Ended 2023-12-31 | $5.14B Ended 2024-03-31 | $5.01B Ended 2023-12-31 | $1.71B Ended 2023-12-31 |
| 3 years earlier | $3.73B Ended 2022-12-31 | $4.54B Ended 2023-03-31 | $4.46B Ended 2022-12-31 | $1.56B Ended 2022-12-31 |
| 4 years earlier | $3.95B Ended 2021-12-31 | $4.22B Ended 2022-03-31 | $5.23B Ended 2021-12-31 | $1.43B Ended 2021-12-31 |